Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, As a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors

Next Previous
Trial Profile

Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, As a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elraglusib (Primary) ; Carboplatin; Doxorubicin; Gemcitabine; Irinotecan; Lomustine; Paclitaxel
  • Indications Adenocarcinoma; Advanced breast cancer; Anaplastic astrocytoma; Appendiceal cancer; Astrocytoma; CNS cancer; Colorectal cancer; Glioblastoma; Glioma; Haematological malignancies; Liver cancer; Male breast cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Oesophageal cancer; Oligodendroglioma; Pancreatic cancer; Pancreatic ductal carcinoma; Parotid cancer; Peritoneal cancer; Precursor T-cell lymphoblastic leukaemia-lymphoma; Renal cell carcinoma; Salivary gland cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms Actuate 1801
  • Sponsors Actuate Therapeutics

Most Recent Events

  • 20 Jun 2025 Results presented in the Actuate Therapeutics Media Release.
  • 02 Jun 2025 According to an Actuate Therapeutics media release, company announced key takeaways from its Key Opinion Leader (KOL) event held on May 31, 2025 followed the presentation of topline trial data during an oral session at the American Society of Clinical Oncology (ASCO) Annual Meeting.
  • 31 May 2025 According to an Actuate Therapeutics media release, Dr. Deva Mahalingam, MD, PhD, Northwestern University Feinberg School of Medicine, is the lead principal investigator of this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top